News Benitec Biopharma Inc. Deutsche Boerse AG

Equities

BJ9

US08205P2092

Delayed Deutsche Boerse AG Other stock markets 02:11:42 2023-07-25 am EDT			5-day change	1st Jan Change
3.06 ^EUR	-2.70%		-.--%	-.--%

May. 13	Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Apr. 22	Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update	May. 13	AQ
Benitec Biopharma : Releases Third Quarter 2024 Financial Results and Provides Operational Update - Form 8-K	May. 13	PU
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 13	CI
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference	May. 01	AQ
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	Apr. 21	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Top Midday Gainers	Apr. 18	MT
Top Premarket Gainers	Apr. 18	MT
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	Apr. 18	AQ
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	Apr. 18	CI
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million	Apr. 18	AQ
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024	Apr. 09	AQ
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update	Feb. 13	AQ
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
JMP Securities Adjusts Benitec Biopharma's Price Target to $8 From $6, Keeps Market Outperform Rating	Jan. 24	MT
Benitec Biopharma Doses First Participant in Trial of Treatment for Oculopharyngeal Muscular Dystrophy	Nov. 30	MT
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	Nov. 30	AQ
Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	Nov. 30	CI
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference	Nov. 17	AQ
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q1 Revenue $0M	Nov. 13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Benitec Biopharma Inc. Deutsche Boerse AG

Equities

BJ9

US08205P2092

Summary

Filters